Topical bevacizumab for the treatment of corneal vascularization in dogs: A case series

Muellerleile, Lisa-Marie; Bernkopf, Michael; Wambacher, Markus; Nell, Barbara

doi:10.1111/vop.12931

Cited by 6 publications

(9 citation statements)

References 60 publications

(119 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Topical bevacizumab 0.25 % q12h in one eye over 28 days was a safe treatment in healthy beagles [17] and adverse effects appeared unlikely in diseased dogs [10]. In the present case, only subconjunctival [18] or intrastromal applications were considered effective since the corneal epithelium was intact.…”

Section: Discussionmentioning

confidence: 68%

“…To achieve the treatment goal of an avascular, immune-privileged cornea, neovascularization can be addressed by a targeted anti-VEGF therapy. While previous publications investigated anti-VEGF-A in human oncology, reports in veterinary literature are sparse [10][11][12].…”

Section: Discussionmentioning

confidence: 99%

“…Recently, Muellerleile et al [10] showed variable reduction of persistent corneal vascularization after topical bevacizumab 0.25 % treatment in dogs. Edelmann et al [11] hypothesized life-long resolution of a sebaceous cell carcinoma in a tiger due to surgical excision combined with intralesional injection of bevacizumab 10 mg. To the authors' knowledge no peer-reviewed literature describing intracorneal bevacizumab 2.5 % administration in horses is available.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Adjunctive bevacizumab therapy in an equine corneal stromal invasive squamous cell carcinoma with a 53-months follow-up

Blohm,

Nell

2024

Tierarztl Prax Ausg G Grosstiere Nutztiere

Self Cite

View full text Add to dashboard Cite

A 17-year-old Appaloosa mare was referred for evaluation of presumed refractory keratitis of the left eye. Gross examination revealed ocular discomfort and corneal neovascularization with a nasal focal opacification affecting approximately 40% of the corneal surface. On ophthalmic examination, extensive subepithelial to mid-stromal vascular branching accompanied by a homogeneous white, dense opacification, which affected up to 80% of the total corneal thickness, were apparent. Signs of concurrent uveitis were absent. Deep-stromal lamellar keratectomy with a conjunctival pedicle graft was performed under general anesthesia. Histopathology confirmed a poorly differentiated corneal stromal invasive squamous cell carcinoma (SI-SCC) with neoplastic cell extension to the surgical margins. Postoperatively, 4 topical mitomycin C 0.04% chemotherapy cycles combined with oral firocoxib therapy were initiated. Seven months after surgery, regrowth of the SI-SCC was clinically suspected. A total volume of 1 ml bevacizumab 2.5% was administered in the standing sedated horse via 3 mid-stromal corneal injections. Four weeks later, intrastromal bevacizumab injections (ISBIs) were repeated, however, this time the solution was injected directly into the main corneal vessel branches.Seven weeks after the second ISBIs, the left eye was comfortable and significant remission of corneal vascularization and opacity was recognized. No recurrence has been noted for a follow-up period of more than 53 months.Equine SI-SCC usually has a very poor prognosis for globe maintenance. To the authors’ knowledge this is the first report of well-tolerated intrastromal antivascular endothelial growth factor adjunctive therapy with bevazicumab 2.5% and SI-SCC resolution after a multimodal treatment approach.

show abstract

Section: Discussionmentioning

confidence: 68%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Adjunctive bevacizumab therapy in an equine corneal stromal invasive squamous cell carcinoma with a 53-months follow-up

Blohm,

Nell

2024

Tierarztl Prax Ausg G Grosstiere Nutztiere

Self Cite

View full text Add to dashboard Cite

show abstract

“…11 In animal models with corneal neovascularization, the levels of expression of vascular endothelial growth factor and its receptors have been found to be increased. 12,13 Research studies conducted on humans have also demonstrated that the expression of vascular endothelial growth factor and its receptors is higher in the cornea of the patients with corneal neovascularization, regardless of the cause. 14 Additionally, the blockage of vascular endothelial growth factor at the level of both mRNA and protein synthesis, has resulted in reduction in corneal neovascularization.…”

Section: Discussionmentioning

confidence: 99%

Effect of Intra-Stromal Bevacizumab on Corneal Vascularization

Niazi¹,

Masood²,

Ali³

et al. 2022

pak J Ophthalmol

View full text Add to dashboard Cite

Purpose: To study the effect of Intra-stromal Bevacizumab on corneal vascularization. Study Design: Quasi experimental study. Place and Duration of Study: Outpatient department of the Combined Military Hospital, Multan from April 2022 to August 2022. Methods: Thirty patients were recruited through non-probability, convenience sampling technique. Ethical approval was taken from Institutional Review Board. Complete ocular examination was performed by a consultant ophthalmologist and patients with corneal neovascularization were included in the study. Area of corneal vascularization was measured on slit lamp. After taking all the aseptic measures and administering anesthetic eye drops, patients were administered 0.2 ml of (2.5 mg/0.1 mL) Bevacizumab (Avastin, Roche) using an ophthalmic microscope. The patient was then called for a follow up after 4 weeks and then the grade of corneal vascularization was checked by a consultant ophthalmologist on slit lamp examination. Data analysis was doneusing SPSS version 25. Results: Mean age of the patients was 43.4 ± 13.7 years (range 25 to 72 years). Male to female ratio was 2:3. There was significant decrease in the area of corneal neovascularization from 2.78mm ± 0.30 to 2.50mm ± 0.27 (p = 0.0003). The mean change in the area of corneal neovascularization was 10.07%. Two patients had sub-conjunctival hemorrhage which settled over due course of time. Conclusion: Intra-stromal Bevacizumab resulted in significant reduction in vascularized area of cornea with minimal side effects indicating that intra-stromal Bevacizumab is an effective and safe modality in the treatment of corneal neovascularization.

show abstract

“… 24 To facilitate the interpretation, only an average score was reported. When the wounds showed no fluorescein uptake, the appearance of the cornea was evaluated clinically to check for the presence of scarring, pigmentation, and vascularization as previously described 25–27 …”

Section: Methodsmentioning

confidence: 99%

Effects of commercial amniotic membrane extract on the re‐epithelialization time and the early expression of matrix metalloproteinase‐9 in cats with experimentally induced corneal ulcers

Silveira

Ribeiro

Pizzinatto

et al. 2022

Veterinary Ophthalmology

View full text Add to dashboard Cite

Objectives: To investigate whether a commercially available amniotic membrane extract (AME) can accelerate corneal wound healing and suppress the early expression of MMP-9 in the tears of cats with experimentally induced superficial ulcerative keratitis.Procedures: A total number of 16 cats were included. At the end of keratectomy, cats in the treatment group (TG, n = 8) received 40 μl of AME (EyeQ® Amniotic Eye Drops, Vetrix®) four times daily, while cats in the control group (CG, n = 8) received 40 μl of saline at the same time points. Tears were collected 24 and 48 h after keratectomy, and the total MMP-9 was quantified by ELISA. Results:The corneal re-epithelialization rate did not differ between groups (p = .26), being 0.48 ± 0.05 mm 2 /h in the CG and 0.41 ± 0.03 mm 2 /h in the TG.Similarly, the average time to achieve corneal wound healing did not differ between groups (p = .25) and was 61.50 ± 3.54 h in the CG and 70.50 ± 6.71 h in the TG. The dimensions of the ulcerated areas also did not differ at any time point between the groups (p > .05). In both groups, corneas healed without scarring, pigmentation, or vascularization. The expression of MMP-9 in the tears was similar in both groups at 24 h post-keratectomy, with a slight decrease at 48 h (p > .05). Conclusions:The instillation of a commercial AME (EyeQ®) is safe, but it did not decrease the corneal re-epithelialization time or the early expression of MMP-9 in the tears of cats with experimentally induced superficial ulcerative keratitis in this study.

show abstract

Topical bevacizumab for the treatment of corneal vascularization in dogs: A case series

Cited by 6 publications

References 60 publications

Adjunctive bevacizumab therapy in an equine corneal stromal invasive squamous cell carcinoma with a 53-months follow-up

Adjunctive bevacizumab therapy in an equine corneal stromal invasive squamous cell carcinoma with a 53-months follow-up

Effect of Intra-Stromal Bevacizumab on Corneal Vascularization

Effects of commercial amniotic membrane extract on the re‐epithelialization time and the early expression of matrix metalloproteinase‐9 in cats with experimentally induced corneal ulcers

Contact Info

Product

Resources

About